DARATUMUMAB
daratumumab 100 mg/5 mL injection, 5 mL vial
DARATUMUMAB (12228N)
12228N
Manner of administration:Injection
Restriction
Indication: Relapsed and/or refractory multiple myeloma
Treatment phase: Initial treatment as second-line drug therapy for weeks 1 to 9 (administered once
weekly)
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1920 mg | # of repeats: 8 | DPMA: $11,190.83 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Darzalex
(daratumumab 100 mg/5 mL injection, 5 mL vial)
|
||||
| Darzalex
(daratumumab 400 mg/20 mL injection, 20 mL vial)
|
||||